(1.17%) 5 123.24 points
(1.16%) 38 667 points
(1.96%) 16 151 points
(-0.60%) $78.48
(5.06%) $2.14
(-0.36%) $2 301.40
(-0.83%) $26.61
(-0.09%) $961.75
(-0.41%) $0.928
(-1.31%) $10.85
(-0.12%) $0.797
(0.40%) $91.49
0.00% $ 1.800
Live Chart Being Loaded With Signals
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments...
Stats | |
---|---|
Volumen de hoy | 1.31M |
Volumen promedio | 41 155.00 |
Capitalización de mercado | 169.54M |
EPS | $0 ( 2024-02-27 ) |
Last Dividend | $0.00500 ( 2023-09-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -36.00 |
ATR14 | $0 (0.00%) |
Cyclopharm Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cyclopharm Ltd Finanzas
Annual | 2023 |
Ingresos: | $27.14M |
Beneficio Bruto: | $4.50M (16.57 %) |
EPS: | $-0.0507 |
FY | 2023 |
Ingresos: | $27.14M |
Beneficio Bruto: | $4.50M (16.57 %) |
EPS: | $-0.0507 |
FY | 2022 |
Ingresos: | $23.22M |
Beneficio Bruto: | $5.94M (25.58 %) |
EPS: | $-0.0717 |
FY | 2021 |
Ingresos: | $17.70M |
Beneficio Bruto: | $12.66M (71.52 %) |
EPS: | $-0.0658 |
Financial Reports:
No articles found.
Cyclopharm Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.00500 (N/A) |
$0 (N/A) |
$0.00500 (N/A) |
$0 (N/A) |
$0.00500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00496 | 2015-10-02 |
Last Dividend | $0.00500 | 2023-09-01 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 17 | -- |
Total Paid Out | $0.0848 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.17 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
IPH.AX | Ex Dividend Knight | 2023-08-22 | Semi-Annually | 0 | 0.00% | |
SHL.AX | Ex Dividend Knight | 2023-09-06 | Semi-Annually | 0 | 0.00% | |
CGF.AX | Ex Dividend Junior | 2023-08-28 | Annually | 0 | 0.00% | |
MIN.AX | Ex Dividend Junior | 2023-09-08 | Annually | 0 | 0.00% | |
TWE.AX | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
DDR.AX | Ex Dividend Knight | 2023-08-16 | Quarterly | 0 | 0.00% | |
NZM.AX | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
ACQ.AX | Ex Dividend Knight | 2023-11-09 | Semi-Annually | 0 | 0.00% | |
GCI.AX | Ex Dividend Knight | 2023-08-31 | Monthly | 0 | 0.00% | |
PTM.AX | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.178 | 1.500 | -3.57 | -5.35 | [0 - 0.5] |
returnOnAssetsTTM | -0.102 | 1.200 | -3.41 | -4.10 | [0 - 0.3] |
returnOnEquityTTM | -0.140 | 1.500 | -2.67 | -4.00 | [0.1 - 1] |
payoutRatioTTM | -0.188 | -1.000 | -1.882 | 1.882 | [0 - 1] |
currentRatioTTM | 3.48 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.26 | 0.800 | 1.391 | 1.113 | [0.8 - 2.5] |
cashRatioTTM | 1.353 | 1.500 | 3.60 | 5.39 | [0.2 - 2] |
debtRatioTTM | 0.0921 | -1.500 | 8.47 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -44.83 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0765 | 2.00 | -0.0255 | -0.0510 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0822 | 2.00 | -0.0411 | -0.0822 | [0 - 20] |
debtEquityRatioTTM | 0.131 | -1.500 | 9.48 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.131 | 1.000 | -1.147 | -1.147 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.368 | 1.000 | -9.35 | -9.35 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.703 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.574 | 0.800 | 9.51 | 7.61 | [0.5 - 2] |
Total Score | -0.485 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -36.03 | 1.000 | -3.74 | 0 | [1 - 100] |
returnOnEquityTTM | -0.140 | 2.50 | -1.714 | -4.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0822 | 2.00 | -0.0274 | -0.0822 | [0 - 30] |
dividendYielPercentageTTM | 0.278 | 1.500 | 3.06 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0765 | 2.00 | -0.0255 | -0.0510 | [0 - 30] |
payoutRatioTTM | -0.188 | 1.500 | -1.882 | 1.882 | [0 - 1] |
pegRatioTTM | 0.146 | 1.500 | -2.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.273 | 1.000 | -9.33 | 0 | [0.1 - 0.5] |
Total Score | -1.924 |
Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico